Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.

Trial Details

NCT ID
NCT05967416
Phase
PHASE1
Sponsor
SIRPant Immunotherapeutics, Inc.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • SIRPant-M
  • External-beam radiotherapy (XRT)
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Adult, defined as age ≥ 18 (at screening), who are willing and able to provide informed consent
  • Must have relapsed/refractory lymphoma, received at least 2 lines of systemic therapy, be ineligible or inappropriate for other treatment regimens …
  • Histologically or cytologically confirmed diagnosis of NHL, any one of the below:
  • Eligible for SIRPant-M monotherapy or SIRPant-M plus focal XRT combination therapy: Diffuse large B-cell lymphoma and cutaneous T-cell lymphoma (CT…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →